179 related articles for article (PubMed ID: 18172284)
1. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma.
Panetta JC; Schaiquevich P; Santana VM; Stewart CF
Clin Cancer Res; 2008 Jan; 14(1):318-25. PubMed ID: 18172284
[TBL] [Abstract][Full Text] [Related]
2. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
Santana VM; Furman WL; Billups CA; Hoffer F; Davidoff AM; Houghton PJ; Stewart CF
J Clin Oncol; 2005 Jun; 23(18):4039-47. PubMed ID: 15961757
[TBL] [Abstract][Full Text] [Related]
3. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors.
Santana VM; Zamboni WC; Kirstein MN; Tan M; Liu T; Gajjar A; Houghton PJ; Stewart CF
Clin Cancer Res; 2003 Feb; 9(2):633-40. PubMed ID: 12576429
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-based models for topotecan-induced neutropenia.
Léger F; Loos WJ; Bugat R; Mathijssen RH; Goffinet M; Verweij J; Sparreboom A; Chatelut E
Clin Pharmacol Ther; 2004 Dec; 76(6):567-78. PubMed ID: 15592328
[TBL] [Abstract][Full Text] [Related]
6. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
Daw NC; Santana VM; Iacono LC; Furman WL; Hawkins DR; Houghton PJ; Panetta JC; Gajjar AJ; Stewart CF
J Clin Oncol; 2004 Mar; 22(5):829-37. PubMed ID: 14990638
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic model of topotecan-induced time course of neutropenia.
Zamboni WC; D'Argenio DZ; Stewart CF; MacVittie T; Delauter BJ; Farese AM; Potter DM; Kubat NM; Tubergen D; Egorin MJ
Clin Cancer Res; 2001 Aug; 7(8):2301-8. PubMed ID: 11489805
[TBL] [Abstract][Full Text] [Related]
9. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
[TBL] [Abstract][Full Text] [Related]
10. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
[TBL] [Abstract][Full Text] [Related]
11. Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study.
Metzger ML; Stewart CF; Freeman BB; Billups CA; Hoffer FA; Wu J; Coppes MJ; Grant R; Chintagumpala M; Mullen EA; Alvarado C; Daw NC; Dome JS
J Clin Oncol; 2007 Jul; 25(21):3130-6. PubMed ID: 17634492
[TBL] [Abstract][Full Text] [Related]
12. Limited sampling model for area under the concentration time curve of total topotecan.
Minami H; Beijnen JH; Verweij J; Ratain MJ
Clin Cancer Res; 1996 Jan; 2(1):43-6. PubMed ID: 9816088
[TBL] [Abstract][Full Text] [Related]
13. Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation.
Delord JP; Léger F; Canal P; Poublanc M; Bugat R; Chatelut E
Cancer Chemother Pharmacol; 2006 Aug; 58(2):189-94. PubMed ID: 16328415
[TBL] [Abstract][Full Text] [Related]
14. Individual adaptive dosing of topotecan in ovarian cancer.
Montazeri A; Culine S; Laguerre B; Pinguet F; Lokiec F; Albin N; Goupil A; Déporte-Féty R; Bugat R; Canal P; Chatelut E
Clin Cancer Res; 2002 Feb; 8(2):394-9. PubMed ID: 11839654
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.
Mould DR; Holford NH; Schellens JH; Beijnen JH; Hutson PR; Rosing H; ten Bokkel Huinink WW; Rowinsky EK; Schiller JH; Russo M; Ross G
Clin Pharmacol Ther; 2002 May; 71(5):334-48. PubMed ID: 12011819
[TBL] [Abstract][Full Text] [Related]
16. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
Loos WJ; Gelderblom H; Sparreboom A; Verweij J; de Jonge MJ
Clin Cancer Res; 2000 Jul; 6(7):2685-9. PubMed ID: 10914710
[TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.
Guichard S; Montazeri A; Chatelut E; Hennebelle I; Bugat R; Canal P
Clin Cancer Res; 2001 Oct; 7(10):3222-8. PubMed ID: 11595718
[TBL] [Abstract][Full Text] [Related]
18. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
McCluskey AG; Boyd M; Ross SC; Cosimo E; Clark AM; Angerson WJ; Gaze MN; Mairs RJ
Clin Cancer Res; 2005 Nov; 11(21):7929-37. PubMed ID: 16278418
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
Hijiya N; Stewart CF; Zhou Y; Campana D; Coustan-Smith E; Rivera GK; Relling MV; Pui CH; Gajjar A
Cancer; 2008 May; 112(9):1983-91. PubMed ID: 18318429
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of periocular topotecan in children with intraocular retinoblastoma.
Chantada GL; Fandino AC; Carcaboso AM; Lagomarsino E; de Davila MT; Guitter MR; Rose AB; Manzitti J; Bramuglia GF; Abramson DH
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1492-6. PubMed ID: 18978345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
